AU2020228514B2 - Cancer therapy using 3,5-disubstituted benzene alkynyl compound and immune checkpoint inhibitor - Google Patents

Cancer therapy using 3,5-disubstituted benzene alkynyl compound and immune checkpoint inhibitor Download PDF

Info

Publication number
AU2020228514B2
AU2020228514B2 AU2020228514A AU2020228514A AU2020228514B2 AU 2020228514 B2 AU2020228514 B2 AU 2020228514B2 AU 2020228514 A AU2020228514 A AU 2020228514A AU 2020228514 A AU2020228514 A AU 2020228514A AU 2020228514 B2 AU2020228514 B2 AU 2020228514B2
Authority
AU
Australia
Prior art keywords
salt
compound
present disclosure
day
nivolumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020228514A
Other languages
English (en)
Other versions
AU2020228514A1 (en
Inventor
Hiroshi Hirai
Kazuaki MATSUOKA
Kazuhiko YONEKURA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of AU2020228514A1 publication Critical patent/AU2020228514A1/en
Application granted granted Critical
Publication of AU2020228514B2 publication Critical patent/AU2020228514B2/en
Priority to AU2025203861A priority Critical patent/AU2025203861A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020228514A 2019-02-28 2020-02-28 Cancer therapy using 3,5-disubstituted benzene alkynyl compound and immune checkpoint inhibitor Active AU2020228514B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025203861A AU2025203861A1 (en) 2019-02-28 2025-05-26 Cancer therapy using 3,5-disubstituted benzene alkynyl compound and immune checkpoint inhibitor

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2019035603 2019-02-28
JP2019-035603 2019-02-28
JP2019-112619 2019-06-18
JP2019112619 2019-06-18
PCT/JP2020/008527 WO2020175704A1 (ja) 2019-02-28 2020-02-28 ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025203861A Division AU2025203861A1 (en) 2019-02-28 2025-05-26 Cancer therapy using 3,5-disubstituted benzene alkynyl compound and immune checkpoint inhibitor

Publications (2)

Publication Number Publication Date
AU2020228514A1 AU2020228514A1 (en) 2021-10-07
AU2020228514B2 true AU2020228514B2 (en) 2025-02-27

Family

ID=72239799

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2020228514A Active AU2020228514B2 (en) 2019-02-28 2020-02-28 Cancer therapy using 3,5-disubstituted benzene alkynyl compound and immune checkpoint inhibitor
AU2020229714A Active AU2020229714B2 (en) 2019-02-28 2020-02-28 Cancer therapy using 3,5-disubstituted benzene alkynyl compound and pembrolizumab
AU2025203865A Pending AU2025203865A1 (en) 2019-02-28 2025-05-26 Cancer therapy using 3,5-disubstituted benzene alkynyl compound and pembrolizumab
AU2025203861A Pending AU2025203861A1 (en) 2019-02-28 2025-05-26 Cancer therapy using 3,5-disubstituted benzene alkynyl compound and immune checkpoint inhibitor

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2020229714A Active AU2020229714B2 (en) 2019-02-28 2020-02-28 Cancer therapy using 3,5-disubstituted benzene alkynyl compound and pembrolizumab
AU2025203865A Pending AU2025203865A1 (en) 2019-02-28 2025-05-26 Cancer therapy using 3,5-disubstituted benzene alkynyl compound and pembrolizumab
AU2025203861A Pending AU2025203861A1 (en) 2019-02-28 2025-05-26 Cancer therapy using 3,5-disubstituted benzene alkynyl compound and immune checkpoint inhibitor

Country Status (8)

Country Link
US (2) US20220184082A1 (enExample)
EP (2) EP3932427A4 (enExample)
JP (6) JPWO2020175697A1 (enExample)
KR (2) KR20210131387A (enExample)
AU (4) AU2020228514B2 (enExample)
MA (2) MA55091A (enExample)
TW (2) TW202039507A (enExample)
WO (2) WO2020175704A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102793563B1 (ko) 2016-03-04 2025-04-11 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP4353222A1 (en) 2018-03-19 2024-04-17 Taiho Pharmaceutical Co., Ltd. Use of sodium alkyl sulfate
PH12022550743A1 (en) * 2019-09-26 2024-06-19 Janssen Pharmaceutica Nv Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
WO2025046272A1 (en) 2023-08-31 2025-03-06 Taiho Pharmaceutical Co., Ltd. Methods of treating cancer using futibatinib and pembrolizumab

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013108809A1 (ja) * 2012-01-19 2013-07-25 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物及びその塩
EP3424505A1 (en) * 2016-03-04 2019-01-09 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040004771A (ko) 2002-07-05 2004-01-16 삼광유리공업주식회사 필름 코팅 유리컵 및 그 제조방법
KR101480809B1 (ko) 2012-03-26 2015-01-09 한국화학연구원 리그닌-폴리에스테르 수지 혼합 분말의 제조 방법 및 이에 따라 제조되는 리그닌-폴리에스테르 수지 혼합 분말
TW201536293A (zh) * 2013-07-18 2015-10-01 Taiho Pharmaceutical Co Ltd 對ｆｇｆｒ抑制劑具耐受性之癌的治療藥
AU2015327868A1 (en) * 2014-10-03 2017-04-20 Novartis Ag Combination therapies
JP6572561B2 (ja) 2015-03-03 2019-09-11 ダイキン工業株式会社 熱交換器および空気調和機
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
AU2016286091B2 (en) * 2015-06-29 2021-02-04 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
CN108368174B (zh) * 2015-11-23 2023-04-14 戊瑞治疗有限公司 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
JP6409797B2 (ja) 2016-02-24 2018-10-24 三菱電機株式会社 冷蔵庫

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013108809A1 (ja) * 2012-01-19 2013-07-25 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物及びその塩
EP3424505A1 (en) * 2016-03-04 2019-01-09 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors

Also Published As

Publication number Publication date
TW202039507A (zh) 2020-11-01
JP2023096156A (ja) 2023-07-06
AU2020228514A1 (en) 2021-10-07
EP3932427A1 (en) 2022-01-05
US20220125793A1 (en) 2022-04-28
JP2025075059A (ja) 2025-05-14
JPWO2020175697A1 (enExample) 2020-09-03
EP3932425A4 (en) 2022-12-07
AU2025203861A1 (en) 2025-06-19
KR20210131387A (ko) 2021-11-02
AU2020229714A1 (en) 2021-10-07
EP3932427A4 (en) 2022-12-07
US20220184082A1 (en) 2022-06-16
JP2023112136A (ja) 2023-08-10
AU2025203865A1 (en) 2025-06-19
WO2020175697A1 (ja) 2020-09-03
MA55091A (fr) 2022-01-05
KR20210130774A (ko) 2021-11-01
JP2024152860A (ja) 2024-10-25
AU2020229714B2 (en) 2025-02-27
EP3932425A1 (en) 2022-01-05
TW202045182A (zh) 2020-12-16
JPWO2020175704A1 (enExample) 2020-09-03
WO2020175704A1 (ja) 2020-09-03
MA55088A (fr) 2022-01-05

Similar Documents

Publication Publication Date Title
AU2020228514B2 (en) Cancer therapy using 3,5-disubstituted benzene alkynyl compound and immune checkpoint inhibitor
JP6894952B2 (ja) 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ
JP2020517640A5 (enExample)
JP2020117524A (ja) 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用
JP2020517640A (ja) 併用療法
TW201625270A (zh) 用於治療贅瘤形成的治療組合及方法
KR20230008197A (ko) 암을 치료하기 위한 방법, 요법 및 용도
JP7402691B2 (ja) 抗ｃｄ２５抗体薬物複合体による併用療法
TWI747868B (zh) 含有免疫調節劑之抗腫瘤劑及抗腫瘤效果增強劑
JP2020517629A5 (enExample)
TW201642897A (zh) Ｈｅｒ２結合劑治療
US20220160718A1 (en) Compositions and methods of treating cancer
EP3066127A1 (en) Immunotherapeutic dosing regimens and combinations thereof
JP2022534889A (ja) Ｃｄｋ阻害剤を使用した組合せ療法
RU2843836C2 (ru) Противораковая терапия с применением соединений 3,5-дизамещенного бензолалкинила и ингибитора иммунной контрольной точки
RU2822064C2 (ru) Противораковая терапия с применением соединений 3,5-дизамещенного бензолалкинила и пембролизумаба
TW202517295A (zh) 包含3,5-二取代苯炔基化合物與免疫檢查點抑制藥之癌症治療法
JPWO2021062244A5 (enExample)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)